Prostate Cancer

An introduction to prostate cancer

Reducing your risk of prostate cancer.

A guide to potential side effects of prostate cancer treatment.

How to deal with sexual dysfunction after prostate cancer.

Prostate cancer screening

Two drugs fail to get FDA approval for prostate cancer prevention.

Pomegranate’s Power Over Prostate Cancer

FDA approved Zytiga (abiraterone) to treat metastatic hormone-resistant prostate cancer.

Preliminary results of two new targeted therapies, now in late-stage clinical trials, hold much promise for men with hormone-refractory, or castration-resistant, prostate cancer.

New developments in the treatment and management of prostate cancer.

New options for advanced prostate cancer mean prolonged remission.

The latest in cancer prevention, diagnosis & treatment

Helping bones stay strong after cancer.

The latest in cancer prevention, diagnosis & treatment.

Metformin, a drug commonly used in the treatment of type 2 diabetes, is showing promise in the treatment of certain types of hormone-stimulated cancers, such as breast cancer and prostate cancer.

Medicines, lifestyle changes and nutrients may help ward off cancer

Interim results from a phase 3 trial showed that radiation added to androgen-deprivation therapy (ADT) increased overall survival and decreased the risk of death from prostate cancer.

Q: What’s different about the new prostate cancer screening guidelines?

Updates from the annual meeting of the American Society of Clinical Oncology.

A growing population of patients have emerged: long-term metastatic cancer survivors.

The latest in cancer prevention, diagnosis, and treatment.

For one side effect of prostate cancer treatment, it takes both the patient and the partner to overcome it.

The FDA decides to wait on reviewing Prolia (denosumab) for reducing treatment-related bone loss in breast and prostate cancer patients, but a new study may shed light on the drug’s importance.

Cooling hot flashes brought on by cancer treatments.

New research highlights drawbacks of tests aimed at early detection.